Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.46 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17234969 | 1.00 | PIK3CD (0.54) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL14719228 | 1.00 | PIK3CD (0.54) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL14729886 | 0.94 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL14726394 | 0.93 | PIK3CD (0.53) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL14726423 | 0.93 | PIK3CD (0.52) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL14729766 | 0.93 | PIK3CD (0.55) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL17234922 | 0.92 | PIK3CD (0.52) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL17235001 | 0.92 | PIK3CD (0.52) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL14726831 | 0.92 | PIK3CD (0.52) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL14729896 | 0.92 | PIK3CD (0.56) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| WO-2015168079-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS PI3K INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| CN-103998442-A | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS INC | 2014-08-20 | — | — | CN | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2751093-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140100214-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| WO-2013032591-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | PIK3CD 5/4885PIK3R1 70/4885PIK3CG 14/4885 |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | PIK3CD 5/4885PIK3R1 70/4885PIK3CG 14/4885 |
| US-20140100214-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | PIK3CD 5/4885PIK3R1 70/4885PIK3CG 14/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | PIK3CD 5/4885PIK3R1 70/4885PIK3CG 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.